Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

Novartis building

Novartis’ Cosentyx cleared for wider use in Europe

Approved for psoriatic arthritis and ankylosing spondylitis

- PMLiVE

Cancer Drugs Fund overhaul promises faster access to drugs

Proposals suggest turning CDF into 'managed access' fund

- PMLiVE

FDA accepts Sandoz filing for biosimilar Neulasta

Theversion of Amgen's blockbuster will have a 10-month review period

- PMLiVE

Repatha’s price tag too rich for UK’s NICE

HTAbody turns the cholesterol-lowering antibody down in draft guidance

- PMLiVE

FDA approves Exelixis/Genentech’s melanoma combo Cotellic

Willprovide the first direct competition to Novartis' Mekinist in the US

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

National Institute for Health and Care Excellence NICE logo

NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira

National Institute for Health and Care Excellence NICE logo

NICE backs use of anti-cholesterol drug Ezetrol

Draft guidance reflects 'greater emphasis on managing CVD risk'

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links